Selvom, der er observeret en lav forekomst af arterielle tromboemboliske tilfælde i de kliniske stuider med Lucentis, så var der ingen ubalance i de behandlede grupper.
A low incidence rate of arterial thromboembolic events was observed in the Lucentis clinical trials and there were no major differences between the treatment groups.